First Bancorp to Announce 1Q 2022 Results on April 28, 2022
SAN JUAN, Puerto Rico–(BUSINESS WIRE)–First BanCorp (the “Corporation”) (NYSE: FBP), the bank holding company for…
SAN JUAN, Puerto Rico–(BUSINESS WIRE)–First BanCorp (the “Corporation”) (NYSE: FBP), the bank holding company for…
An economic solution for large wounds treated in the out-patient care setting PHOENIX–(BUSINESS WIRE)–#SAWC–Kerecis®, the…
2021 – FOURTH QUARTER AND FISCAL YEAR RESULTS FOURTH QUARTER 2021 HIGHLIGHTS INVOICED SALES INCREASED…
Highlights Include Company’s Progress in the Following Areas: Advances in the Research, Development, and Manufacturing…
SANTA MONICA, Calif.–(BUSINESS WIRE)–BlackRock TCP Capital Corp. (NASDAQ: TCPC) announced today that it will report…
VERO BEACH, Fla.–(BUSINESS WIRE)–Orchid Island Capital, Inc. (NYSE:ORC) (“Orchid” or the “Company”), a real estate…
OXFORD, England & VIENNA, Austria–(BUSINESS WIRE)–Exscientia plc (Nasdaq: EXAI) today shared details of its participation…
The partnership includes designation as the “Official Bank” of the first-ever United States Mint Negro…
SOUTH SAN FRANCISCO, Calif., April 08, 2022 (GLOBE NEWSWIRE) — Nkarta, Inc. (Nasdaq: NKTX), a…
The recommended phase 2 dose was determined at 480 mg AFM24 has demonstrated a well-managed…
– Toripalimab plus chemotherapy provided superior progression free survival, overall survival, overall response rate and…
– Poster presentations showcase SAFEbody® precision masking technology applicability across targets and modalities – –…
– First rigorous analysis estimates TSC1 and TSC2 definite impact alteration incidence in U.S. as…
Preclinical data featured in three posters show potential of KB-0742 in triple-negative breast, lung and…
VIP152 demonstrates antitumor responses in preclinical models of gynecologic malignancies Preliminary monotherapy clinical results presented…
– Data highlight PYX-106’s differentiated activity profile and antitumor activity in an in vivo mouse…
TCXpress™ identified a diverse set of novel T-cell receptors (TCRs) with in vitro reactivity against…
BOSTON, April 08, 2022 (GLOBE NEWSWIRE) — X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in…
ZURICH, Switzerland, April 08, 2022 (GLOBE NEWSWIRE) — Araris Biotech AG, a company pioneering a…
GEN-011 shows consistent pattern of activity in first five heavily pre-treated, checkpoint-refractory patients with…